AzTrials
AzTrials

Metastatic Breast CancerABLE02NCT04354233

A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer

A study testing Physical activity intervention with connected devices in people with Metastatic Breast Cancer, run by Centre Leon Berard at 18 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

INTRODUCTION: Patients with a metastatic breast cancer suffer from a deteriorated quality of life and numerous symptoms such as pain, severe fatigue and a decrease of their physical fitness. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Metastatic Breast Cancer
What is being tested?
Physical activity intervention with connected devices
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
124 participants
Where
18 sitesFrance
Study dates
24 Jun 2020to 30 Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1) female,
  • 2) ≥ 18 years old,
  • 3) histologically confirmed metastatic breast cancer, with at least one positive hormone receptor (HR+) and HER2-,
  • 4) first-line chemotherapy planned (or until 1 month after the chemotherapy has started) with intravenous (Paclitaxel or Doxorubicin or Cyclophosphamide or Carboplatin) or per os (Capecitabine or Vinorelbine) administration - NB : a patient who has previously received one or more lines of hormone therapy and who must start a 1st line of chemotherapy is eligible,
  • 5) Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2,
  • 6) life expectancy ≥ 3 months,
Show all 12Show fewer
  • 7) willing to be involved throughout the study,
  • 8) ability to practice a adapted physical activity (APA) certified by a medical certificate issued by the referring oncologist or the clinical investigator,
  • 9) using a compatible smartphone or Tablet PC to download the application ABLE02 and Withings Health Mate (from iOS 10 and android 6.0 and more recent),
  • 10) Internet access,
  • 11) valid health insurance affiliation,
  • 12) able to read, write and understand French.

Who cannot join

  • 1) presence of unstable bone metastases or unconsolidated pathological fractures,
  • 2) presence of central nervous system involvement with neurological deficits that prevent from walking,
  • 3) presence of a history or co-existence of other primary cancer (except of in situ cancer regardless of the site and/or basal cell skin cancer and/or non-mammary cancer in complete remission for more than 5 years),
  • 4) severe undernutrition (HAS) (i.e. for women ≤ 70 years old: a weight loss of ≥ 15% in 6 months or ≥10% in 1 month and for women over 70 years old: a weight loss of ≥ 15% in 6 months or ≥10% in 1 month, and body mass index <18 kg/m²),
  • 5) presenting a PA contraindication (e.g., uncontrolled hypertension, uncontrolled heart disease),
  • 6) concurrent participation in another PA study,
Show all 9Show fewer
  • 7) unable to be followed for medical, social, family, geographical or psychological reasons throughout the study,
  • 8) deprived of liberty by judicial or administrative decision,
  • 9) pregnant.

Trial locations and contacts

18 sites in 1 country.

18 sites in 1 country

France18 sites
  • CHU Amiens

    Amiens

  • Institut de Cancérologie de l'Ouest (ICO)

    Angers

  • CHU Avignon

    Avignon

  • CH Fleyriat

    Bourg-en-Bresse

  • CH Cotentin

    Cherbourg

  • CH Cholet

    Cholet

  • CGFL

    Dijon

  • Groupement Hospitalier Mutualiste

    Grenoble

  • Centre Léon Bérard (CLB)

    Lyon, 69008

  • Hospices Civils de Lyon

    Lyon

  • CH Morlaix

    Morlaix

  • AP-HP

    Paris

  • Institut Curie

    Paris

  • Institut Godinot

    Reims

  • Centre Eugène Marquis

    Rennes

  • Institut de Cancérologie Lucien Neuwirth (ICLN)

    Saint-Etienne

  • Institut de Cancérologie de l'Ouest (ICO)

    Saint-Herblain

  • Institut Gustave Roussy

    Villejuif

Other trials in France

About this study

Official title: A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer

INTRODUCTION: Patients with a metastatic breast cancer suffer from a deteriorated quality of life and numerous symptoms such as pain, severe fatigue and a decrease of their physical fitness. As the feasibility of a physical activity program has been demonstrated in this population, ABLE02 aims to assess the efficacy of a 6 month-physical activity program based on connected devices to improve health-related quality of life and to reduce fatigue in women with metastatic breast cancer.

METHODS/ANALYSIS: ABLE02 is a prospective, multicenter, randomized, controlled and, open-label study. 244 patients with a metastatic breast cancer , at least one positive hormone receptor and a first-line chemotherapy planned will be randomly assigned (1:1 ratio) to: (i) the intervention arm to receive physical activity recommendations, an activity tracker to wear 24 hours a day during the whole intervention (6 months) with at least three walking sessions weekly and quizzes to answer each week on physical activity and nutrition (ii) the control arm to receive physical activity recommendations only. Assessments will be conducted at baseline, M3, M6, M12 and M18 to evaluate the clinical, physical, biological and psychological parameters and survival of participants. All questionnaires will be completed on a dedicated application.

DISCUSSION: An activity program based on smartphone application linked to an activity tracker may help to improve quality of life and reduce fatigue of patients with a metastatic breast cancer. The growth of e-health offers the opportunity to get real-time data as well as improving patient empowerment in order to change long-term behaviors.

Being tested
Physical activity intervention with connected devices
Keywords
Metastatic breast cancer, Physical activity, Connected devices, e-Health, Quality of life, Fatigue
Medical subject headings
Breast Neoplasms, Motor Activity, Fatigue

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Physical activity intervention with connected devicesDevice

    Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the "Withings Health Mate" application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team.

Study groups in NCT04354233
Study groupRoleWhat they receive
Physical activity intervention with connected devicesExperimentalWomen randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
Receives: Device: Physical activity intervention with connected devices
Standard careNo interventionWomen will receive stardard care and physical activity international recommendations, without further intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. time to deterioration of global health status (GHS) score of EORTC QLQ C30

    Health-Related Quality of Life (HRQoL) and fatigue will be measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life Questionnaire (QLQ-C30). QLQ-C30 questionnaire consists of 30 items to evaluate 5 functioning domains (physical, role, emotional, cognitive, and social), a global HRQoL domain, 3 symptom domains (pain, fatigue and nausea) and 6 single items (dyspnea, insomnia, anorexia, diarrhea, constipation and financial impact). Participants will answer to a Likert scale ranging from "not at all" to "very much" and from "very bad" to "excellent" only for the global HRQoL questions. All scores will be standardized to a 0 to 100 scale according to the EORTC scoring manual. Higher scores represent better functioning, better global HRQoL and greater symptom burden.

    Deterioration is defined as a 5-point decrease relative to baseline in GHS score, with no subsequent increase above this threshold.

    Measured: Month 18

  2. time to deterioration of fatigue score of EORTC QLQ C30

    Health-Related Quality of Life (HRQoL) and fatigue will be measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life Questionnaire (QLQ-C30). QLQ-C30 questionnaire consists of 30 items to evaluate 5 functioning domains (physical, role, emotional, cognitive, and social), a global HRQoL domain, 3 symptom domains (pain, fatigue and nausea) and 6 single items (dyspnea, insomnia, anorexia, diarrhea, constipation and financial impact). Participants will answer to a Likert scale ranging from "not at all" to "very much" and from "very bad" to "excellent" only for the global HRQoL questions. All scores will be standardized to a 0 to 100 scale according to the EORTC scoring manual. Higher scores represent better functioning, better global HRQoL and greater symptom burden.

    A deterioration of fatigue is defined as a 5-point increase relative to baseline fatigue score, with no subsequent decrease above this threshold.

    Measured: Month 18

Secondary outcomes (22)
  1. Overall survival

    Period from the date of randomization to the date of event defined as death from any cause

    Measured: Month 18

  2. Progression free survival

    Period from the date of randomization to the date of event defined as progression of the disease or death from any cause

    Measured: Month 18

  3. Other dimensions of health-related quality of life of the EORTC QLQ C30

    Health-Related Quality of Life (HRQoL) and fatigue will be measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life Questionnaire (QLQ-C30). QLQ-C30 questionnaire consists of 30 items to evaluate 5 functioning domains (physical, role, emotional, cognitive, and social), a global HRQoL domain, 3 symptom domains (pain, fatigue and nausea) and 6 single items (dyspnea, insomnia, anorexia, diarrhea, constipation and financial impact). Participants will answer to a Likert scale ranging from "not at all" to "very much" and from "very bad" to "excellent" only for the global HRQoL questions. All scores will be standardized to a 0 to 100 scale according to the EORTC scoring manual. Higher scores represent better functioning, better global HRQoL and greater symptom burden.

    All of the secondary health-related quality of life dimensions except the global score and fatigue are evaluated.

    Measured: Baseline, Month 3, Month 6, Month 12

  4. Fatigue

    Multidimensional aspects of fatigue will be assessed by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-FA12 cancer related fatigue module. EORTC QLQ-FA12 consists of 12 items to evaluated physical, cognitive and emotional domains of cancer-related fatigue. Participants will answer to a 4-points Likert scale ranging from "not at all" to "very much". All scores will be transformed to a 0 to 100 scale and higher scores will indicate greater degree of fatigue.

    Measured: Baseline, Month 3, Month 6, Month 12

  5. Proportion of patients who change their physical condition (6-min walking distance)

    6-min walking distance

    Measured: Change between baseline, Month 3, Month 6 and Month 12

  6. Proportion of patients who change their physical condition (sit-to-stand)

    Sit-to-stand

    Measured: Change between baseline, Month 3, Month 6 and Month 12

  7. Proportion of patients who change their physical condition (handgrip strength)

    Handgrip strength

    Measured: Change between baseline, Month 3, Month 6 and Month 12

  8. Proportion of patients who change their weight

    Body weight (kg)

    Measured: Change between baseline, Month 3, Month 6 and Month 12

  9. Proportion of patients who change their waist circumference

    Waist circumference (cm)

    Measured: Change between baseline, Month 3, Month 6 and Month 12

  10. Proportion of patients who change their hip circumference

    Hip circumference (cm)

    Measured: Change between baseline, Month 3, Month 6 and Month 12

  11. Proportion of patients who change their physical activity level

    PA level will be measured by the Godin Leisure-Time Exercise Questionnaire (GSLTPAQ). The GSLTPAQ is a short validated self-administrated physical activity (PA) questionnaire which includes three main questions about frequency of low (e.g., easy walking), moderate (e.g., brisk walking), and strenuous (e.g., jogging) leisure-time PA of at least 15 minutes duration in a typical week. The total score is obtained by multiplying frequencies from mild, moderate and strenuous PA by three, five and nine metabolic equivalents respectively and adding these together. Finally this score is divided into three categories (≥ 24 units is equivalent to mild active; between 14 and 23 units is equivalent to moderately active and < 14 units is equivalent to insufficiently active).

    Measured: Change between baseline, Month 3, Month 6 and Month 12

  12. Proportion of patients who change sleep disorders

    Perceived sleep quality will be measured with the Pittsburgh Sleep Quality Index (PSQI) evaluating seven sleep components: (1) sleep quality, (2) sleep latency, (3) sleep duration, (4) habitual sleep efficiency, (5) sleep disturbance, (6) use of sleeping medication, and (7) daytime dysfunction. Each of the seven components is rated on a Likert scale from "Not during last month" (0) to "3 or 4 times per week" (3). The total score resulting from the sum of the seven components ranges from 0 to 21, and a cut off 5 has been found to reflect clinically significant sleep disturbances.

    The quality of sleep will also be evaluated by the activity tracker based on automatic recognition of total duration of sleep, duration of deep and light sleep per night for the intervention arm only.

    Measured: Change between baseline and Month 6

  13. Proportion of patients who loss muscle mass (sarcopenia)

    CT scans

    Measured: Change between baseline, Month 3, Month 6, Month 12 and at first progression up to Month 18

  14. Proportion of patients who change their dietary patterns

    Dietary patterns will be assessed using a qualitative food frequency questionnaire composed of 35 items. Participants will answer the question "how frequently do you consume this product" on a Likert-type scale ranging from "never or almost" to "once per day or more" (stating quantity only for the range "once per day or more"). The questionnaire will characterize the consumption of fruits, vegetables, cereals, milk, dairy products, bread, meat, fish, poultry, eggs, starches, plant fat, desserts, sweetened products, non-alcoholic beverages, cold cuts, fried food, fast foods, preprepared meals, crackers, and snacking.

    Measured: Change between baseline and Month 6

  15. Proportion of patients who have severe toxicity (grade > 2)

    Occurrence of severe toxicity (grade > 2) according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE)

    Measured: Month 12

  16. Proportion of patients who have modifications in inflammation and sarcopenia according to blood sample analysis

    Two 10mL blood samples will be collected before each physical assessment and before starting chemotherapy and at 1st progression.

    The following assays will be performed on plasma for the assessment of inflammation and biomarker of sarcopenia: Myostatin, Activin, Cortisol, TNF-alpha, IFN-gamma, IL-1beta, IL-6, Follistatin, GDF5 (BMP14), IL-10, IL-15, NH3, Aminogram.

    The levels of lymphocytes, monocytes, neutrophils will be extracted from the data of the routine blood test.

    Measured: Change between baseline, Month 3, Month 6, Month 12 and at first progression up to Month 18

  17. Proportion of patients who have modifications on oxidative stress according to blood sample analysis

    Two 10mL blood samples will be collected before each physical assessment and before starting chemotherapy and at 1st progression.

    The following assays will be performed on plasma for the assessment of oxidative stress: Advanced oxidation protein products (AOPP), malondialdehyde (MDA), Superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), Xanthine oxidase (XO), and Myeloperoxidase (MPO).

    Measured: Change between baseline, Month 3, Month 6, Month 12 and at first progression up to Month 18

  18. Proportion of patients who modify their personnality factors

    Based on the Five-Factor Model, personality traits will be assessed by the French Big Five Inventory questionnaire (BFI-Fr). The BFI-Fr contains 45 self-descriptive statements that assess the 5 personality traits: neuroticism (which refers to a propensity to experience negative emotions, distress, and anxiety), extraversion (a propensity to be energetic, sociable, and experience positive emotions); openness to experience (the tendency to be curious, imaginative, and to entertain new ideas, values, and experiences); conscientiousness (reflecting self-disciplined, planful, and organized); and agreeableness (which refers to cooperativeness and altruism). Each item was rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). All items will be recoded in the direction of the trait label, and the mean will be taken across items for each personality trait.

    Measured: Change between baseline and Month 6

  19. Proportion of patients who modify their behaviour in association with physical activity

    The process of change will be evaluated by a validated scale constructs from the transtheoretical model. The process of change scale is a 22-item self-administrated questionnaire to measure eight process of change: self-reevaluation (item 4,8 and 12), reinforcement management (items 7,15 and 12), self-liberation (items 8, 16 and 22), dramatic relief (items 2 and 10), environmental reevaluation (items 3 and 11), counterconditioning (items 5, 13 and 19), helping relationships (items 6, 14 and 20) and consciousness raising (items 1, 9 and 17). Participants will answer to a Likert scale ranging from 1 (never) to 5 (very often). Items in each process of change will be added and then an average score will be calculated. When the average is ≥ 3, the process of change is activated.

    Measured: Change between baseline and Month 6

  20. Proportion of patients who accept the connected device (in the intervention arm only)

    Acceptability questionnaire will be assessed by a 21-item questionnaire to evaluate satisfaction concerning the use of connected devices (application, website, quizz, activity tracker).

    Measured: Month 6

  21. Proportion of patients who are compliant to the PA intervention (in the intervention arm only)

    Performed 3 PA sessions per week

    Measured: Month 6

  22. Proportion of patients who modify their cognition

    The cancer-related cognitive impairment will be measured by the Functional Assessment of Cancer Therapy-Cognition (FACT-Cog). The FACT-Cog is a validated self-administrated questionnaire in order to assess memory, attention, concentration, language, and thinking abilities. The questionnaire is composed of 37 items with four subscales: patients' perceived cognitive impairments, perceived cognitive abilities, deficits observed or commented on by others, and impact of cognitive changes on HRQoL. Participant will answer how often this situation occurred during the last 7 days on a Likert-type scale ranging from "never" to "several times a day". For both scales, higher scores indicated better perceived cognitive function.

    Measured: Change between baseline, Month 6 and Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2020
  2. Study start24 Jun 2020
  3. Primary completion30 Jun 2024
  4. Study completion30 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
At the first visit of the study, participants will be randomly assigned (1:1 ratio), with minimization based on the presence of visceral metastases (presence vs. absence of visceral metastases), the method of administration of chemotherapy (intravenous vs. per os) and the 6-minute walking distance (6MWD) (\<455 versus ≥ 455m based on the median of the pilot ABLE study) to: (i) the intervention arm to receive PA recommendations and benefit from a 6-month APA program (ii) the control arm to receive PA recommendations only.
Masking
None (open label)
Enrolment
124 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04354233
Sponsor's protocol ID
ABLE02
Other IDs
ET20-022
Acronym
ABLE02
Status last verified
Apr 2026
First submitted
14 Apr 2020
Last updated
4 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Delrieu L, Anota A, Tredan O, Freyssenet D, Maire A, Canada B, Fournier B, Febvey-Combes O, Pilleul F, Bouhamama A, Caux C, Joly F, Fervers B, Pialoux V, Perol D, Perol O. Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health-related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial. BMC Cancer. 2020 Jul 3;20(1):622. doi: 10.1186/s12885-020-07093-9.

    PubMed 32620149

Questions about this trial

What is this clinical trial studying?

A study testing Physical activity intervention with connected devices in people with Metastatic Breast Cancer, run by Centre Leon Berard at 18 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

time to deterioration of global health status (GHS) score of EORTC QLQ C30 (time frame: Month 18). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04354233, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in